Duchenne Muscular Dystrophy — the most common severe childhood muscular dystrophy, where the specific DMD variant determines which of the emerging exon-skipping therapies a child is eligible for.
Whole genome sequencing reads the entire DMD gene — the largest gene in the human genome at 2.4 million base pairs — capturing all deletion breakpoints, duplications, and deep intronic variants that determine both diagnosis and treatment eligibility.
Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular disorder caused by pathogenic variants in the DMD gene on chromosome Xp21.2, which encodes dystrophin — a structural protein essential for muscle fiber membrane integrity. Dystrophin deficiency leads to progressive muscle fiber degeneration, chronic inflammation, and replacement of muscle tissue with fibrotic and adipose tissue. DMD is the most common severe childhood muscular dystrophy, affecting approximately 1 in 3,500-5,000 male births worldwide. Onset typically occurs between ages 2-5 years with proximal muscle weakness, manifesting as difficulty running, climbing stairs, and rising from the floor (Gowers sign). Without treatment, loss of ambulation occurs by age 12-13, and death from respiratory or cardiac failure typically occurs in the late teens to mid-twenties.
Approximately 60-70% of DMD-causing variants are large deletions spanning one or more exons, concentrated in two hotspot regions (exons 2-20 and exons 44-55). Large duplications account for 5-15% of variants, and the remaining 20-30% are point mutations (nonsense, frameshift, splice site). The reading frame rule distinguishes DMD from the milder allelic condition Becker muscular dystrophy (BMD): out-of-frame variants that eliminate functional dystrophin production cause DMD, while in-frame variants that produce truncated but partially functional dystrophin cause BMD. This genotype-phenotype correlation guides prognosis and increasingly guides treatment selection.
The DMD treatment landscape has been transformed by genotype-specific precision therapies. Exon-skipping antisense oligonucleotides — eteplirsen (exon 51, ~13% of DMD patients), golodirsen/viltolarsen (exon 53, ~8%), and casimersen (exon 45, ~8%) — restore the reading frame to produce truncated but functional dystrophin, converting a DMD phenotype toward BMD. Ataluren targets nonsense (premature stop codon) variants, which account for approximately 10-15% of cases. Gene replacement therapy (delandistrogene moxeparvovec, approved 2023) uses micro-dystrophin delivered via AAV vector. Each of these therapies requires definitive DMD variant characterization to determine eligibility — making the genetic diagnosis not just diagnostic but directly therapeutic.
The reading frame rule determines whether a DMD variant produces Duchenne (severe, out-of-frame) or Becker (milder, in-frame) muscular dystrophy. Precise breakpoint characterization determines exon-skipping therapy eligibility — a decision that depends on knowing which exons are affected.
Standard deletion/duplication testing identifies the exons involved but not the precise intronic breakpoints. Deep intronic variants causing aberrant splicing are invisible to exon-focused panels. Whole genome sequencing provides the complete variant architecture.
Precise deletion breakpoints determine exon-skipping eligibility — exon-level testing alone is insufficient
MLPA (multiplex ligation-dependent probe amplification) — the standard first-tier DMD diagnostic test — identifies which exons are deleted or duplicated but cannot resolve intronic breakpoint locations with base-pair precision. For exon-skipping therapy eligibility, the exact breakpoint location determines whether the therapeutic exon skip can restore the reading frame. Additionally, complex rearrangements — inversions, non-contiguous deletions, and insertion-deletions — are not reliably detected by MLPA. Whole genome sequencing maps deletion breakpoints to the nucleotide level across all 79 DMD exons and the intervening 2.2 million base pairs of intronic sequence.
20-30% of DMD variants are point mutations that require full-gene sequencing to detect
One-third of DMD patients have point mutations — nonsense, frameshift, or splice site variants — rather than large deletions or duplications. MLPA does not detect point mutations; these patients require full DMD gene sequencing as a second diagnostic step. Among point mutation patients, those with premature stop codon (nonsense) variants may be eligible for ataluren therapy. Deep intronic variants that create cryptic splice sites represent an additional category detectable only by sequencing beyond the coding exons. Whole genome sequencing captures deletions, duplications, point mutations, and deep intronic variants in a single test — eliminating the sequential multi-test diagnostic pathway.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Duchenne Muscular Dystrophy and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
